A Study to Evaluate Dupilumab as a Treatment for Moderate-to-Severe, Chronic Hepatic Pruritus

Overview

About this study

The purpose of this study is to investigate the potential effectiveness of dupilumab in the treatment of moderate-to-severe, chronic hepatic pruritus.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male and/or female subjects.
  • 18 years or older.
  • Chronic pruritus of moderate-to-severe severity in the setting of intrahepatic or extrahepatic cholestatic liver disease. Chronic is defined as greater than 6 weeks of symptom duration.
  • Documentation of a personally signed and dated informed consent indicating that the subject or their legally acceptable representative has been informed of all pertinent aspects of the trial.
  • Willingness and ability to comply with scheduled clinic visits, physical exams, laboratory tests, questionnaires, and other trial procedures.

Exclusion Criteria:

  • Male and/or female subjects under 18 years of age.
  • Pruritus due to a primary inflammatory skin dermatosis or other forms of psychogenic pruritus utilizing skin biopsies as needed.
  • Pregnant females.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Jason Sluzevich, M.D.

Closed for enrollment

Contact information:

Rachel Pung Page

(904)953-8513

White.Rachel2@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20476147

Mayo Clinic Footer